Metformin in Dengue With Obesity — MeDO  

Obesity Clinical Trial

Official title: Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial

Status Completed

Clinical Trial Summary

This study aims to investigate the effect of metformin as host-directed therapy in obese/overweight patients with dengue Primary Objective To evaluate the safety and tolerability of metformin in obese/overweight young adults and children with dengue Secondary Objectives - To assess the effect of metformin therapy in obese/overweight patients with dengue on physiological, clinical and virological parameters - To assess the immunomodulation effects of metformin therapy in obese/overweight patients with dengue - To assess difference in gene expression between treatment group compared to non-treatment population

Clinical Trial Description

This is an open-label safety and tolerability study investigating the effects of five days of metformin treatment. The metformin therapy will be given to eligible participants admitted to the Hospital for Tropical Diseases (HTD) in Ho Chi Minh City, Vietnam. The 60 patients receiving metformin intervention will be compared to 60 age-matched overweight or obese controls, who get the standard supportive treatment only. The intervention will be conducted in two phases, with a dose escalation. In the initial phase (cohort 1), five young adults (16-30 years) and five children (age 10-16 years) with body mass index (BMI) >25 kg/m2 (BMI-for-age >1 standard deviation - SD) will be provided with a low dose of metformin once daily at 850mg and 500mg respectively. A Data Monitoring Committee (DMC) review will take place after day 5 data is fully available for the first ten patients enrolled in cohort 1. If the five-day safety and clinical data of cohort 1 show no safety concerns, the study will progress to the second phase (cohort 2). This will include 25 adults and 25 children, who will be given a weight-based dose of metformin; 1000mg (500mg twice daily) for participants with weight < 60kg, and 1500mg (1000mg mane, 500mg nocte) for those ≥ 60kg. Patients that are admitted to the HTD within 72 hours of fever, with clinical suspicion of dengue, will be invited to participate in the trial. After giving consent, patients will be screened for their eligibility to commence treatment with the trial drug. Blood samples will be collected to test for NS1, pregnancy (in all female patients), and AST, ALT and creatinine levels. Glucose and lactate levels will be measured using point-of-care (POC) tests. All patients will be asked to come back for a final FU visit at around 21-28 days after the onset of fever. Details of all AEs and SAEs will be recorded on specific forms, together with an assessment as to whether the events are likely to have been related to any treatment received. All SAEs will be reported promptly to the DMC and ECs according to policy. In cases of discontinuation due to AEs, participants will be followed up until the events have resolved or stabilized. ;

Related Conditions & MeSH terms

• Anti-inflammatory Agents
• Dengue
• Metformin
• Obesity
• Overweight
• Viral Infection
• Virus Diseases

• NCT number: NCT04377451
• Study type: Interventional
• Source: Oxford University Clinical Research Unit, Vietnam
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: July 27, 2020
• Completion date: August 1, 2023